• AAPL 195.71
  • TSLA 243.84
  • AMZN 147.42
  • BTC-USD 44395.7891
  • ETH-USD 2364.7615
  • EURUSD 1.0764
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. ALPMY.US

Astellas Pharma Inc (ALPMY PINK) stock market data APIs

$12.55 0.29(2.4%) as of December 7, 2023

Astellas Pharma Inc Financial Data Overview

12.26
12.55
-
12.55
12.11
11.25-16.91
21 525 M
92.1539
1 797 M
1 523 572 M
-0.0053
0.0369
0.424
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ALPMY',
Type: 'Common Stock',
Name: 'Astellas Pharma Inc',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000NVQS78',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'March',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers-General',
GicSector: NULL,
GicGroup: NULL,
GicIndustry: NULL,
GicSubIndustry: NULL,
HomeCategory: 'ADR',
IsDelisted: false,
}

Astellas Pharma Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 1 523 572 M
  • EBITDA 263 774 M
  • Earnings Per Share 0.13
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Astellas Pharma Inc Earnings via APIs

  • Latest Release 2023-10-31
  • EPS/Forecast 0.1781

Get Astellas Pharma Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Astellas Pharma Inc latest news via APIs

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

– Results of pivotal confirmatory trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall survival and progression-free survival vs standard platinum contain...

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com